

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

IIDA=20

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

10/069755

INTERNATIONAL APPLICATION NO.
PCT/JP00/05922

INTERNATIONAL FILING DATE
31 August 2000

PRIORITY CLAIMED
31 August 1999

TITLE OF INVENTION
SOFT CAPSULES

APPLICANT(S) FOR DO/EO/US
Yoshimitsu IIDA et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- a. [] is attached hereto (required only if not transmitted by the International Bureau).
- b. [X] has been communicated by the International Bureau.
- c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [X] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
- b. [] have been communicated by the International Bureau.
- c. [] have not been made; however, the time limit for making such amendments has NOT expired.
- d. [X] have not been made and will not be made.
8. [] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: _____

[X] Courtesy copy of the first page of the International Publication (WO 01/15702).
[X] Courtesy copy of the International Preliminary Examination Report. There were no annexes
[X] Courtesy Copy of the International Search Report.
[X] Application Data Sheet

[X] The application is (or will be) assigned to: CHUGAI SEIYAKU KABUSHIKI KAISHA whose address is 41-8, Takada 3-chome, Toshima-ku, Tokyo 171-8545 Japan.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/069755		International Application No. PCT/JP00/05922		Attorney's Docket No. IIDA=20	
17. [xx] The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims as Originally Presented	Number Filed 7 - 20	Number Extra	Rate X \$18.00	\$	
Total Claims	2 - 3		X \$84.00	\$	
Independent Claims			X \$84.00	\$	
Multiple Dependent Claims (if applicable)			+\$280.00	\$ 280.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,170.00	
Claims After Post Filing Prel. Amend	Number Filed - 20	Number Extra	Rate X \$18.00	\$	
Total Claims	- 3		X \$84.00	\$	
Independent Claims			X \$84.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,170.00	
Reduction of ¼ for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.				\$	
SUBTOTAL =				\$1,170.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1,170.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$1,170.00	
				Amount to be: refunded	\$
				charged	\$
a. [] A check in the amount of \$_____ to cover the above fees is enclosed. b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 1,170.00, is attached. c. [] Please charge my Deposit Account No. 02-4035 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. d. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, N.W., SUITE 300 WASHINGTON, D.C. 20001 TEL: (202) 628-5197 FAX: (202) 737-3528 Date of this submission: February 28, 2002 Form PTO-1390 (as slightly revised by Browdy and Neimark)					
				 SIGNATURE Roger L. Browdy NAME 25 618 REGISTRATION NUMBER	

SPECIFICATION
SOFT CAPSULE FORMULATIONS

TECHNICAL FIELD

5 The present invention relates to soft capsule formulations containing active vitamins D₃.

BACKGROUND ART

10 Active vitamins D₃ such as 1 α -hydroxycholecalciferol (1 α -hydroxyvitamin D₃) and 1 α ,25-dihydroxycholecalciferol (1 α ,25-dihydroxyvitamin D₃) have the effects of promoting calcium absorption in the small intestine, controlling bone metabolism in the bone, controlling parathyroid hormone production in the parathyroid, inducing differentiation in
15 tumor cells, suppressing immune response, etc. Therefore, they are considered to be effective for treating renal failure associated with lowered calcium absorption, osteoporosis caused by abnormal bone metabolism, hyperparathyroidism, malignant tumors, autoimmune diseases
20 and the like.

 However, all these compounds are unstable to light and heat and to be put to use in medical applications, this problem is required to be overcome. Formulations containing active vitamins D₃ as active ingredients are
25 used at varying active ingredient levels because the dose varies with the disease or condition. Thus, it is important that the active ingredient level in each formulation can be readily discriminated in order to

10669755-022802

prevent medical fault.

It is also important to ensure content uniformity of active vitamins D₃ in formulations because they are effective at a very low dose such as several tens of
5 micrograms.

Known formulations of active vitamins D₃ include a soft capsule formulation of an active vitamin D₃ wherein an oily solution of the active vitamin D₃ is encapsulated with a capsule shell containing 1.0% by weight or less of a UV
10 absorber having a light transmittance of 10% or less at a wavelength of 310 mμ in 0.01% by weight aqueous solutions and having absorption in the visible range (JPA No. 84023/1979). Other soft capsule formulations for stabilizing light-unstable compounds so far reported
15 include a soft capsule formulation wherein a dye absorbing a specific wavelength of light and an opacifier are homogeneously dispersed in a gelatin shell (JPA No. 28621/1973); a soft capsule formulation wherein Food Color Yellow No. 5 is homogeneously dispersed in a soft capsule
20 shell to stabilize light-unstable compounds in said soft capsule shell (JPA No. 22645/1980); a soft capsule formulation wherein an edible tar-based dye such as Food color Yellow No. 4 is dispersed in a capsule shell (JPA No. 13511/1983), etc. However, recent scientific research has
25 shown that a UV absorber having absorption in the visible range, and dyes used in these disclosed techniques, which are tar-based synthetic dyes or synthetic colorants, have doubtful safety. Moreover, these formulations are

inconvenient for international distribution because the permitted classes of dyes vary between countries.

On the other hand, a method for stabilizing active vitamins D₃ without using a tar-based synthetic dye or a synthetic colorant is known, such as a soft capsule formulation using a capsule shell containing a natural dye such as cocoa dye, apigenin, carminic acid, carminic acid lake, laccaic acid or shikonin (JPA No. 53923/1987). However, it is difficult to always maintain a uniform color tone with these natural dyes, which vary in color tone with the batch lot, and also tend to be unstable.

A method for stabilizing active vitamins D₃ by using an inorganic compound is also known, such as a soft capsule formulation using a capsule shell containing fine particles of titanium oxide wherein at least 85% of titanium oxide has a particle diameter of 0.1 μ m or less (JPA No. 166824/1988). However, titanium oxide has a white color tone, which is insufficient for discriminating active ingredient levels and requires some additional colorants to enable better discrimination.

Known colorants other than the above tar-based dyes, synthetic colorants and natural dyes include iron oxide, caramel and the like. A soft capsule formulation using iron oxide is described in JPA No. 84023/1979, which discloses a soft capsule formulation of an active vitamin D₃ encapsulated with a shell containing yellow iron oxide and red iron oxide, but it is reported to be insufficient in stability to heat. A method for preventing

destabilization of active ingredients due to direct contact of the active ingredients with red iron oxide (diiron trioxide) in soft capsule shells is reported by JPA No.

157911/1989, which discloses a light-screening capsule

- 5 formulation wherein microencapsulated red iron oxide is dispersed in a shell to prevent direct contact of red iron oxide with the drug in the capsule, but this method is not a practical means of production since it requires complex operations such as the preparation of microcapsules
- 10 containing red iron oxide. A gelatin shell colored with caramel (JPA No. 127448/1980) is also known, but its effect on the stability of active vitamins D₃ to light or heat is unknown.

15 DISCLOSURE OF THE INVENTION

- The present invention provides soft capsule formulations of active vitamins D₃ well-suited to practical production with easy discrimination of active ingredient levels, in which stability of the active vitamins D₃ to
- 20 light and heat is ensured by using a material which is highly safe to the human body.

- As a result of careful studies, the inventors accomplished the present invention on the basis of the finding that soft capsule formulations of active vitamins
- 25 D₃ with excellent stability to light and heat and good discrimination that can be prepared by a process well-suited to practical production can be obtained by using a capsule shell containing a white pigment and yellow iron

oxide and/or red iron oxide, or a white pigment and caramel.

Accordingly, the present invention provides a soft capsule formulation comprising: an oily solution of an active vitamin D₃; and a soft capsule shell which contains
5 a white pigment and yellow iron oxide and/or red iron oxide and encapsulates the oily solution of an active vitamin D₃.

The present invention also provides a soft capsule formulation comprising: an oily solution of an active vitamin D₃; and a soft capsule shell which contains a white
10 pigment and caramel and encapsulates the oily solution of active vitamin D₃.

PREFERRED EMBODIMENTS OF THE INVENTION

The present application claims priority based on
15 Japanese Patent Application No. 244828/1999, the disclosure of which is wholly incorporated herein as a reference.

Active vitamins D₃ used in the present invention include, for example, 1 α -hydroxyvitamin D₃, 24-hydroxyvitamin D₃, 25-hydroxyvitamin D₃, 1 α ,24-dihydroxyvitamin D₃, 1 α ,25-dihydroxyvitamin D₃, 1 α ,24,25-trihydroxyvitamin D₃, 22-oxa-1 α ,25-dihydroxyvitamin D₃ and 2 β -(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃,
20 preferably 1 α -hydroxyvitamin D₃ and 2 β -(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃.

25 Examples of the white pigments used in the present invention include titanium oxide, calcium carbonate and alumina, preferably titanium oxide and calcium carbonate, more preferably titanium oxide.

10069755-022802

Examples of the titanium oxide used in the present invention includes titanium dioxide (TiO_2) of anatase and rutile types, both of which are commercially available, with the anatase type being preferred. The particle diameter of the titanium oxide is not particularly limited, however those having an average particle diameter of 0.2-0.5 μm are used in general; those having smaller particle diameters can be also employed. Such titanium oxide treated to improve resistance to discoloration as described in JPA No. 222442/1999 may also be used. The content of the titanium oxide used is preferably 98.5% by weight or more expressed as dry content.

The amount of white pigment used is preferably 0.1% by weight or more, particularly 0.5% by weight or more, of the total amount of capsule shell components. It is preferably 1.5% by weight or less, particularly 1.0% by weight or less, of the total amount of capsule shell components.

As used herein, the total amount of capsule shell components means the amount of the materials of capsule shell excluding water.

Yellow iron oxide used in the present invention is $\text{Fe}_2\text{O}_3 \cdot (\text{H}_2\text{O})$, also called yellow diiron trioxide. Commercially available yellow iron oxide can be conveniently used, but the content of diiron trioxide in the ignition product is preferably 98.0% or more.

Red iron oxide used in the present invention is Fe_2O_3 , also called diiron trioxide or red oxide. Commercial products can be conveniently used, but the content of

diiron trioxide in the ignition product is preferably 98.0% or more.

1069755-022802

If the capsule shell components include a white pigment and yellow iron oxide and/or red iron oxide, the amount of white pigment and yellow iron oxide and/or red iron oxide contained in the capsule shell depends on the light screening properties, heat resistance and desired color tone of the capsule shell, but the total amount of white pigment, yellow iron oxide and red iron oxide is preferably 0.11% by weight or more, more preferably 0.51% by weight or more of the total amount of capsule shell components. It is preferably 1.51% by weight or less, more preferably 1.1% by weight or less of the total amount of capsule shell components. The total amount of yellow iron oxide and red iron oxide contained in the capsule shell may be preferably 0.01% or more and 1.0% by weight or less. Here, either one or both of yellow iron oxide and red iron oxide can be used.

In order to control color tone, a dye such as caramel can further be added.

Caramel used in the present invention is obtained by heat-treating an edible carbohydrate such as D-glucose, sucrose, invertose, millet jerry, starch hydrolyzate, molasses, etc. The molecular weight of caramel is not particularly limited, but a caramel product free from components having a molecular weight below a certain value as described in JPA No. 127448/1980 may be used.

If caramel is contained in the capsule shell in the

present invention, the amount of caramel contained in the capsule shell depends on the desired color tone and strength of the capsule shell, but preferably ranges from 0.05 to 1.5% by weight of the total amount of capsule shell components. If caramel is contained in the capsule shell, a white pigment is preferably also contained in the capsule shell. The total amount of white pigment and caramel contained in the capsule shell depends on the desired color tone and strength of the capsule shell, but it is preferably 0.15% by weight or more and 1.55% or less of the total amount of capsule shell components. If capsule shell components include a white pigment and caramel, yellow iron oxide and/or red iron oxide may further be contained as capsule shell components, and in this case, the total amount of the white pigment, caramel, yellow iron oxide and red iron oxide is preferably 1.56% or less of the total amount of capsule shell components.

Other components of soft capsule shells may be those capable of forming a soft capsule shell with a white pigment and yellow iron oxide and/or red iron oxide or with a white pigment and caramel or the like, such as various gelatins and various plasticizers in combination with various additives. Examples of the various gelatins include gelatins derived from animals such as cattle and swine. As used herein, various gelatins include alkali-treated gelatins, acid-treated gelatins, chemically modified gelatins or the like, which may be used alone or in admixture.

Alkali-treated gelatins mean those obtained by hydrolyzing a raw material of gelatin such as collagen or ossein with an alkaline material such as a lime solution, and extracting the hydrolyzate; while acid-treated gelatins are those obtained by hydrolyzing a collagen with an acidic material such as dilute hydrochloric acid or dilute sulfuric acid. Chemically modified gelatins generally mean, but are not limited to, those prepared by reacting the amino group of a gelatin with an acid such as succinic acid, phthalic acid or acetic acid. Either the alkali-treated gelatins or the acid-treated gelatins may be used for preparing the chemically modified gelatins.

Examples of the various plasticizers include glycerin, sorbitol, maltose, glucose, maltitose, sucrose, xylitol, mannitol, erythritol, polyethylene glycols (molecular weight 400-6000), etc.

Examples of the various additives include ethyl paraoxybenzoate, propyl paraoxybenzoate, potassium sorbate, etc.

The thickness of the capsule shells may be appropriately chosen in as far as the soft capsule formulations maintain sufficient strength and disintegrate at an appropriate timing to release active vitamins D₃ when they are administered; the thickness is preferably 200 μ m to 600 μ m.

Preferably, the white pigment, yellow iron oxide and red iron oxide are homogeneously dispersed in a capsule shell. They can be dispersed by adding a mixed suspension

of the white pigment and yellow iron oxide and/or red iron oxide or a mixed solution of the white pigment and caramel to a gelatin solution or adding and dispersing the white pigment into a gelatin solution and then adding yellow iron
5 oxide and/or red iron oxide or caramel. The order of addition is not specifically limited. These white pigment, yellow iron oxide, red iron oxide and caramel can be homogeneously dispersed in a gelatin solution by using a conventional stirring or dispersing method and apparatus.

10 Suitable bases for the oily solutions may be those capable of forming a soft capsule formulation without impairing stability of active vitamins D₃, such as glycerides of fatty acids, propylene glycol fatty acid diesters, triacetin, polyethylene glycols, vegetable oils,
15 etc., preferably glycerides of fatty acids, particularly preferably middle chain fatty acid triglycerides. These oily bases may be used alone or as a mixture of two or more. As used herein, the middle chain fatty acid triglycerides mean those based on a fatty acid triglyceride in which the
20 fatty acid has a carbon chain length of 8-10. Examples of the vegetable oils include olive oil, soybean oil, rapeseed oil, castor oil, etc., which may be used alone or as a mixture of two or more.

The soft capsule formulations of the present invention
25 can be prepared, for example, by encapsulating an oily solution of an active vitamin D₃ described above in a soft capsule shell described above using a rotary or dropping-type continuous soft capsule machine.

EXAMPLES

The following examples further illustrate the present invention without, however, limiting the invention thereto.

Example 1

5 To a solution of 1α -hydroxyvitamin D_3 dissolved at a concentration of 1.44 mg/ml in absolute ethanol was added a middle chain fatty acid triglyceride (The Nisshin Oil Mills Ltd.) to give an oily solution of 1α -hydroxyvitamin D_3 at a concentration of 4.8 μ g/ml. Separately, a gelatin solution
10 was prepared containing 38 parts by weight of gelatin (Nitta Gelatin Inc.), 11 parts by weight of glycerin (Kashima Chemical Co., Ltd.), 0.15 parts by weight of potassium sorbate and 50 parts by weight of purified water as well as titanium oxide (A-100, Ishihara Sangyo Kaisha,
15 Ltd.), yellow iron oxide (Kishi Kasei Co., Ltd.) and red iron oxide (Kishi Kasei Co., Ltd.) in the amounts shown in Table 1 below. The oily 1α -hydroxyvitamin D_3 solution was encapsulated with the above gelatin solution containing titanium oxide, yellow iron oxide and/or red iron oxide
20 using a continuous soft capsule machine (SPHEREX, Freund Industrial Co., Ltd.) and dried in a tumbler dryer to prepare soft capsules.

The resulting soft capsules had an average weight of 101 mg per capsule and an average solution content of 61 mg.
25 These capsules had good color tone and discrimination from capsules obtained in other examples as evaluated by organoleptic tests (visual tests).

Comparative example 1

Soft capsules were prepared in the same manner as in Example 1 above except that the gelatin solution contained none of titanium oxide, yellow iron oxide and red iron oxide.

The resulting soft capsules had an average weight of 100 mg per capsule and an average solution content of 60 mg.

Comparative example 2

Soft capsules were prepared in the same manner as in Example 1 above except that the gelatin solution contained titanium oxide in the amount shown in Table 1 below instead of titanium oxide, yellow iron oxide and red iron oxide.

The resulting soft capsules had an average weight of 101 mg per capsule and an average solution content of 63 mg.

Example 2

Soft capsules were prepared in the same manner as in Example 1 above except that instead of titanium oxide, yellow iron oxide and red iron oxide, the gelatin solution contained titanium oxide and yellow iron oxide in the amounts shown in Table 1 below.

The resulting soft capsules had an average weight of 106 mg per capsule and an average solution content of 64 mg. These capsules had good color tone and discrimination as evaluated in the same manner as in Example 1.

Example 3

Soft capsules were prepared in the same manner as in Example 1 above except that instead of titanium oxide, yellow iron oxide and red iron oxide, the gelatin solution contained titanium oxide and yellow iron oxide in the amounts shown in Table 1 below.

The resulting soft capsules had an average weight of 100 mg per capsule and an average solution content of 60 mg. These capsules had good color tone and discrimination as evaluated in the same manner as in Example 1.

Example 4

Soft capsules were prepared in the same manner as in Example 1 above except that instead of titanium oxide, yellow iron oxide and red iron oxide, the gelatin solution contained titanium oxide and caramel in the amounts shown in Table 1 below.

The resulting soft capsules had an average weight of 103 mg per capsule and an average solution content of 63 mg. These capsules had good color tone and discrimination as evaluated in the same manner as in Example 1.

Example 5

Soft capsules were prepared in the same manner as in Example 1 above except that instead of titanium oxide, yellow iron oxide and red iron oxide, the gelatin solution contained titanium oxide and caramel in the amounts shown in Table 1 below.

The resulting soft capsules had an average weight of

100 mg per capsule and an average solution content of 61 mg. These capsules had good color tone and discrimination as evaluated in the same manner as in Example 1.

5 Table 1. Charges of titanium oxide, yellow iron oxide and red iron oxide

Soft capsule	Titanium oxide	Yellow iron oxide	Red iron oxide	Caramel
Example 1	0.80	0.09	0.01	-
Example 2	0.85	0.05	-	-
Example 3	0.60	0.30	-	-
Example 4	0.50	-	-	1.00
Example 5	1.00	-	-	0.10
Comparative example 1	-	-	-	-
Comparative example 2	1.00	-	-	-

In Table 1 above, each value represents the charge (expressed in % by weight) of each component relative to the total amount of the materials of the shell (excluding water). "-" means that the component is not added.

Example 6

To a solution of 2 β -(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃ dissolved at a concentration of 0.488 mg/ml in absolute ethanol was added a middle chain fatty acid triglyceride (The Nisshin Oil Mills Ltd.) to give an oily solution of 2 β -(3-hydroxypropyloxy)-1 α ,25-

1069755-022602
dihydroxyvitamin D₃ at a concentration of 8.0 µg/ml.

Separately, a gelatin solution was prepared containing 38 parts by weight of gelatin (Nitta Gelatin Inc.), 11 parts by weight of glycerin (Kashima Chemical Co., Ltd.) and 50

5 parts by weight of purified water as well as titanium oxide (A-100, Ishihara Sangyo Kaisha, Ltd.) and red iron oxide (Kishi Kasei Co., Ltd.) in the amounts shown in Table 2 below. The oily 2β-(3-hydroxypropyloxy)-1α,25-

dihydroxyvitamin D₃ solution was encapsulated with the above gelatin solution containing titanium oxide and red iron oxide using the continuous soft capsule machine to prepare soft capsules.

The resulting soft capsules had an average weight of 100 mg per capsule and an average solution content of 60 mg.

15 These capsules had good color tone and discrimination as evaluated in the same manner as in Example 1.

Comparative example 3

Soft capsules were prepared in the same manner as in Example 6 above except that the gelatin solution contained neither titanium oxide nor red iron oxide.

The resulting soft capsules had an average weight of 100 mg per capsule and an average solution content of 60 mg.

25 Comparative example 4

Soft capsules were prepared in the same manner as in Example 6 above except that the gelatin solution contained titanium oxide in the amount shown in Table 2 below in

addition to 35 parts by weight of gelatin, 12 parts by weight of glycerin and 53 parts by weight of purified water.

The resulting soft capsules had an average weight of 170 mg per capsule and an average solution content of

5 100 mg.

Table 2. Charges of titanium oxide, yellow iron oxide and red iron oxide

Soft capsule	Titanium oxide	Yellow iron oxide	Red iron oxide	Caramel
Example 6	0.6	-	0.3	-
Comparative example 3	-	-	-	-
Comparative example 4	1.00	-	-	-

10 In Table 2 above, each value represents the charge (expressed in % by weight) of each component relative to the total amount of the materials of the shell (excluding water). "-" means that the component is not added.

15 Test example 1: Accelerated light stability testing 1

Soft capsules prepared in Examples 1-5 and Comparative examples 1 and 2 above were left for 171 hours under fluorescent lighting at 3500 lux (integrated illumination 600,000 lux.hr) and then measured for the residual level of

20 1 α -hydroxyvitamin D₃ by high performance liquid chromatography under the measurement conditions below. Color tone stability was also evaluated by visually

comparing the color tone of soft capsules after irradiation to the color tone of non-irradiated soft capsules.

Measurement conditions for the residual level:

Apparatus: a high performance liquid chromatography

- 5 made by Shimadzu Corporation (autoinjector SIL-10A, solvent delivery unit LC-10AD, system controller SCL-10A, detector SPD-10A, column oven CTO-10A/10AC, chromatopack C-R7Apuls)

Column: Waters Symmetry C18 3.5um 4.6 x 150 mm

- Sample volume: 200 µL (sample concentration: about
10 125 ng/ml)

Column temperature: 25°C

Mobile phase: acetonitrile:water:tetrahydrofuran:acetic
acid = 1350:400:250:1 (v/v)

Flow rate: 1 ml/min

- 15 Detector: UV detector at 265 nm.

The measurement results are shown in Table 3. These
results showed that soft capsules of the present invention
have excellent light stability. Soft capsules of the
present invention were also found to have excellent
20 stability in color tone under irradiation.

Table 3. Residual level of 1α -hydroxyvitamin D₃ in accelerated light stability testing

Soft capsule	Residual level (%)
Example 1	95.2
Example 2	98.1
Example 3	99.1
Example 4	95.5
Example 5	97.4
Comparative example 1	52.4
Comparative example 2	96.2

Test example 2: Accelerated light stability testing 2

5 Soft capsules prepared in Example 6 and Comparative examples 3 and 4 above were left for 200 hours under fluorescent lighting at 3000 lux (integrated illumination 600,000 lux.hr) and then measured for the residual level of 2β -(3-hydroxypropyloxy)- 1α ,25-dihydroxyvitamin D₃ by high
10 performance liquid chromatography under the measurement conditions below. Color tone stability was also evaluated by visually comparing the color tone of soft capsules after irradiation to the color tone of non-irradiated soft capsules.

15 Measurement conditions for the residual level:

Apparatus: a high performance liquid chromatography made by Shimadzu Corporation (autoinjector SIL-10A, solvent delivery unit LC-10AD, system controller SCL-10A, detector SPD-10A, column oven CTO-10AC)

20 Analyzer: Waters Millennium 32

Column: YMC A-004 SIL 5um 4.6 x 300 mm

Sample volume: 50 µL (sample concentration: about 5 ng/ml)

Column temperature: 25°C

5 Mobile phase: dichloromethane:methanol:acetic acid:water = 1000:15:13:3.5 (v/v)

Flow rate: 1.8 ml/min

Detector: UV detector at 265 nm.

10 The measurement results are shown in Table 4. These results showed that soft capsules of the present invention have excellent light stability. Soft capsules of the present invention were also found to have excellent stability in color tone under irradiation.

15 Table 4. Residual level of 2β-(3-hydroxypropyloxy)-1α,25-dihydroxyvitamin D₃ in accelerated light stability testing

Soft capsule	Residual level (%)
Example 6	97.5
Comparative example 3	1.4
Comparative example 4	95.1

Test example 3: Accelerated heat stability testing

20 Soft capsules prepared in Examples 1-5 and Comparative examples 1 and 2 above were stored at 50°C for 1 month and then measured for the residual level of 1α-hydroxyvitamin D₃ by high performance liquid chromatography under the same measurement conditions as in Test example 1 above. The measurement results are shown in Table 5. These results

showed that soft capsules of the present invention have sufficient thermal stability.

Table 5. Residual level of 1 α -hydroxyvitamin D₃ in
5 accelerated heat stability testing

Soft capsule	Residual level (%)
Example 1	90.9
Example 2	85.5
Example 3	89.0
Example 4	90.0
Example 5	85.3
Comparative example 1	91.5
Comparative example 2	87.6

INDUSTRIAL APPLICABILITY

Soft capsule formulations of the present invention are useful as soft capsule formulations of active vitamins D₃,
10 because they have great advantages such as (i) excellent stability to light and heat, (ii) good discrimination with controllable color tone, (iii) excellent safety due to the use of a white pigment, yellow iron oxide, red iron oxide and caramel widely known as safe to human, (iv) excellent
15 stability in color tone, (v) suitability for practical production, etc.

CLAIMS

1. A soft capsule formulation comprising:
an oily solution of an active vitamin D₃; and
a soft capsule shell which contains a white pigment and yellow iron oxide and/or red iron oxide and encapsulates said oily solution of an active vitamin D₃.
2. A soft capsule formulation comprising:
an oily solution of an active vitamin D₃; and
a soft capsule shell which contains a white pigment and caramel and encapsulates said oily solution of active vitamin D₃.
3. The capsule formulation of Claim 1 or 2 wherein the white pigment is titanium oxide.
4. The soft capsule formulation of any one of Claims 1 to 3 wherein the base for the oily solution is at least one selected from fatty acid glycerides, propylene glycol fatty acid diesters, triacetin, polyethylene glycols and vegetable oils.
5. The soft capsule formulation of Claim 4 wherein the base for the oily solution comprises a fatty acid glyceride.
6. The soft capsule formulation of any one of Claims 1 to 5 wherein the active vitamin D₃ is selected from 1 α -hydroxyvitamin D₃, 24-hydroxyvitamin D₃, 25-hydroxyvitamin D₃, 1 α ,24-dihydroxyvitamin D₃, 1 α ,25-dihydroxyvitamin D₃, 1 α ,24,25-trihydroxyvitamin D₃, 22-oxa-1 α ,25-dihydroxyvitamin D₃ and 2 β -(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃.

ABSTRACT

An object of the present invention is to provide soft capsule formulations of active vitamins D₃ well-suited to
5 practical production with easy discrimination of active ingredient levels, in which stability of the active vitamins D₃ to light and heat is ensured, and which material is highly safe to the human body. According to the present invention, soft capsule formulations of active
10 vitamins D₃ can be obtained wherein the capsule shell contains a white pigment and yellow iron oxide and/or red iron oxide, or titanium oxide and caramel, or yellow iron oxide.

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

SORT CAPSULE FORMULATIONS

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appl. No. _____*; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/JP00/05922 filed Aug. 31, 2000, entry requested on _____*; national stage application received U.S. Appl. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on _____ (if applicable).

(Include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

<u>244828/1999</u>	<u>Japan</u>	<u>31/8/1999</u>	<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO
(Number)	(Country)	(Day Month Year Filed)		
_____	_____	_____	<input type="checkbox"/> YES	<input type="checkbox"/> NO
(Number)	(Country)	(Day Month Year Filed)		

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under §119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)
_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)
_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444; i.e.,
BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from **YUASA AND HARA** as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

10062755-022802

Title: SOFT CAPSULE FORMULATIONS
 U.S. Application filed _____ Serial No. _____
 PCT Application filed August 31, 2000 Serial No. PCT/JP00/05922

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR <u>Yoshimitsu IIDA</u>		INVENTOR'S SIGNATURE <u>Yoshimitsu Iida</u>	DATE Dec.28, 2001
RESIDENT Tokyo, Japan		CITIZENSHIP Japanese JBX	
POST OFFICE ADDRESS <u>c/o CHUGAI SEIYAKU KABUSHIKI KAISHA of 41-8, Takada 3-chome,</u> <u>Toshima-ku, Tokyo 171-8545 Japan</u>			
FULL NAME OF SECOND JOINT INVENTOR <u>Yutaka OGAWA</u>		INVENTOR'S SIGNATURE <u>Yutaka Ogawa</u>	DATE Dec.28, 2001
RESIDENT Tokyo, Japan		CITIZENSHIP Japanese JPA	
POST OFFICE ADDRESS <u>c/o CHUGAI SEIYAKU KABUSHIKI KAISHA of 5-1, Ukima 5-chome,</u> <u>Kita-ku, Tokyo 115-8543 Japan</u>			
FULL NAME OF THIRD JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SIGNED BY ALL INVENTORS.